Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Deferred Income Tax
The difference between tax expense recognized and tax actually paid in cash during the period.
Atrium Therapeutics, Inc.NASDAQ: RNA
Deferred Income Tax · Q1 FY2026 · quarter ended Mar 2026
Deferred income tax of $0 in Q1 FY2026
Q1 FY2026 deferred income tax was $0.
Context
- Deferred income tax amounted to 0.8% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Deferred Income Tax history
USD · from the cash flow
- Latest · FY2025
- (142K) USD
- Year-over-year change
- —
| Period | Period end | Deferred Income Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (142K) | — |
Deferred Income Tax vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Deferred Income Tax figures are available to compare.
Cash Flow Statement
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.